Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             212 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Acknowledgements
33 S2 p. v
 artikel
2 Editorial Board
33 S2 p. i
 artikel
3 ELCC 2022 Organisation
33 S2 p. xii
 artikel
4 ESMO
33 S2 p. vii
 artikel
5 ESTRO
33 S2 p. ix
 artikel
6 ESTS
33 S2 p. x
 artikel
7 ETOP
33 S2 p. xi
 artikel
8 IASLC
33 S2 p. viii
 artikel
9 172MO Analysis of comutations in DNA damage repair (DDR) related pathways with immunotherapeutic biomarkers in Chinese lung cancer patients Li, J.
33 S2 p. S111
 artikel
10 2MO Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC Lu, S.
33 S2 p. S27
 artikel
11 4MO Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study Yang, Y.
33 S2 p. S28
 artikel
12 3MO First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small cell lung cancer: Updated overall survival results from the phase III CameL-sq trial Zhou, C.
33 S2 p. S28
 artikel
13 157MO Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy Casarrubios, M.
33 S2 p. S105
 artikel
14 7MO Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial Zhou, C.
33 S2 p. S31
 artikel
15 81MO Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated results Lyu, C.
33 S2 p. S71-S72
 artikel
16 5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON Garon, E.B.
33 S2 p. S29-S30
 artikel
17 6MO Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up Rodriguez Abreu, D.
33 S2 p. S30-S31
 artikel
18 109MO Respect the middle lobe: Perioperative survival of bilobectomy compared to lobectomy and pneumonectomy Li, A.
33 S2 p. S82
 artikel
19 82MO Risk-adjusted mortality rates as a quality proxy outperform volume in lung cancer surgery: A new perspective on hospital centralization using national population-based data Baum, P.
33 S2 p. S72
 artikel
20 108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6) Garassino, M.C.
33 S2 p. S81-S82
 artikel
21 8MO The efficacy and safety of TQ-B3101 monotherapy in the first-line treatment in patients with ROS1-positive non-small cell lung cancer Lu, S.
33 S2 p. S31
 artikel
22 131MO Trends in age and sex specific lung cancer mortality in Europe and Northern America: Analysis of vital registration data from the WHO mortality database between 2000 and 2017 Baum, P.
33 S2 p. S93
 artikel
23 Notice and Disclaimer
33 S2 p. iii
 artikel
24 80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study Felip, E.
33 S2 p. S71
 artikel
25 141O Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study Reinmuth, N.
33 S2 p. S97-S98
 artikel
26 1O Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: A randomized, double-blind, multi-center, phase III study (FURLONG) Shi, Y-K.
33 S2 p. S27
 artikel
27 57P Acquired concurrent EGFR T790M and driver gene resistance from EGFR-TKIs hampered osimertinib efficacy in advanced lung adenocarcinoma Wu, F.
33 S2 p. S58-S59
 artikel
28 162P A CT radiomics model to predict overall survival following curative-intent radiotherapy for stage I-III non-small cell lung cancer Hindocha, S.
33 S2 p. S107
 artikel
29 70P Adherence to treatment recommendations from multidisciplinary tumor boards Roeper, J.
33 S2 p. S63
 artikel
30 85P Adjuvant osimertinib in patients (pts) with stage IB–IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection: ADAURA China subgroup analysis Jie, W.
33 S2 p. S73
 artikel
31 33P A literature review of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) caused by immune checkpoint inhibitors (ICIs), epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and multikinase inhibitors (MKIs) Hu, Z.
33 S2 p. S47
 artikel
32 105P A model of workflow for radiomics signature of stage III non-small cell lung cancer (NSCLC) patients (pts) Ferro, A.
33 S2 p. S79-S80
 artikel
33 196P An international consensus on actions to improve lung cancer survival: A clinical review by the international cancer benchmarking partnership (ICBP) Lynch, C.
33 S2 p. S119-S120
 artikel
34 181P Anlotinib enhances the antitumor activity of high-dose irradiation combined with anti-PD-L1 by potentiating the tumor immune microenvironment in murine lung cancer Yuan, M.
33 S2 p. S114
 artikel
35 73P A novel nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer Cao, S.
33 S2 p. S64
 artikel
36 163P Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: Findings from the CAVE-lung trial Della Corte, C.M.
33 S2 p. S107-S108
 artikel
37 30P A phase I, dose-escalation and dose-expansion study of SY-3505: A third-generation ALK TKI in Chinese ALK-positive advanced non-small cell lung cancer Shi, Y-K.
33 S2 p. S45
 artikel
38 12P A phase II study of atezolizumab in combination with bevacizumab, carboplatin or cisplatin, and pemetrexed for EGFR-mutant metastatic NSCLC patients after failure of EGFR TKIs Wu, S-G.
33 S2 p. S33-S34
 artikel
39 107P Application of contrast clearance analysis (CCA) to assess viable tumour in non-small cell lung cancer (NSCLC) brain metastases post-stereotactic radiosurgery (SRS) Mohamedkhan, S.
33 S2 p. S80
 artikel
40 58P A predictive model of the diagnostic value of next generation sequencing based genomics testing in patients with metastatic non-small cell lung cancer in Spain Mota, A.
33 S2 p. S59
 artikel
41 189P Assessment of seroconversion after SARS-CoV2 vaccination in patients with lung cancer Trontzas, I.P.
33 S2 p. S117
 artikel
42 198P Association between BTLA polymorphisms and NSCLC risk Andrzejczak, A.
33 S2 p. S120
 artikel
43 86P Aumolertinib as adjuvant therapy in postoperative EGFR-mutated non-small cell lung cancer Zhang, Q.
33 S2 p. S73
 artikel
44 161P Bayesian network structure for predicting two-year survival inpatients diagnosed with non-small cell lung cancer Osong, B.
33 S2 p. S107
 artikel
45 65P Blood cytokine changes in patients with advanced NSCLC receiving immunotherapy Schindler, H.L.
33 S2 p. S61-S62
 artikel
46 29P Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results Tiseo, M.
33 S2 p. S44-S45
 artikel
47 16P Camrelizumab monotherapy or plus apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A single-arm, open-label, multicenter, phase II study Zhao, M.
33 S2 p. S36-S37
 artikel
48 26P Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung Cancer (aNSCLC): Updated results from GEOMETRY mono-1 Wolf, J.
33 S2 p. S42
 artikel
49 126P Characteristics and postoperative trajectory of patients requiring ICU admission following radical surgery for mesothelioma Chandarana, K.
33 S2 p. S90
 artikel
50 169P Characteristics of clonal hematopoiesis (CH) in patients with non-small cell lung cancer (NSCLC): A retrospective analysis of plasma cell-free DNA (cfDNA) comprehensive genomic profiling Tagliamento, M.
33 S2 p. S110
 artikel
51 168P Characterization of the lung tumor microenvironment upon anti-PD-L1 therapy reveals an ambiguous role for TNF-α De Ridder, K.
33 S2 p. S109
 artikel
52 147P Chemo-immunotherapy with or without consolidative radiotherapy in extensive-stage small cell lung cancer: An initial report of clinical outcome and safety Bruni, A.
33 S2 p. S100-S101
 artikel
53 186P CIP2A modulates PKM2 dimer-tetramer transition through phosphorylation of serine 287 in non-small cell lung cancer Liang, L.
33 S2 p. S115-S116
 artikel
54 123P Clinical and environment factors impacting malignant pleural mesothelioma prognosis Deboever, N.O.T.
33 S2 p. S89
 artikel
55 64P Clinical benefit of platinum doublet therapy for elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the national hospital organization in Japan Shimokawa, M.
33 S2 p. S61
 artikel
56 98P Clinical characteristic of women under 55 years old who qualified for surgical treatment of lung cancer: Analysis of 1574 cases Trojnar, A.
33 S2 p. S77
 artikel
57 50P Clinical characteristics, treatment patterns and outcomes of EGFR exon 20 insertion and other EGFR mutations in Korean aNSCLC patients Yoon, S.
33 S2 p. S56
 artikel
58 68P Clinical implications of cardiotoxicity and pharmacokinetics of alectinib in patients (pts) with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) Pruis, M.
33 S2 p. S63
 artikel
59 145P Clinical outcomes of atezolizumab in combination with etoposide/platinum for extensive-stage small cell lung cancer in China: A real-world, multi-center, retrospective, controlled study Zhuo, M.
33 S2 p. S100
 artikel
60 179P Clinical profile of SMARCA4/SMARCB1-mutated non-small cell lung carcinomas: A retrospective study in a Spanish institution Fernandez, G.
33 S2 p. S113
 artikel
61 59P Clinical utility of plasma cell-free DNA EGFR mutation analysis in treatment-naïve stage IV non-small cell lung cancer patients Kim, B-G.
33 S2 p. S59
 artikel
62 185P Clinicopathological characterization of NGS detected mutations in lung cancers: A single center experience Walter, J.
33 S2 p. S115
 artikel
63 101P Clinicopathological features and behavior of ground glass opacity lung cancer associated with cystic airspace Yu, Z.
33 S2 p. S78
 artikel
64 170P Clonal hematopoiesis in asymptomatic individuals enrolled in a lung cancer screening program Montuenga, L.
33 S2 p. S110
 artikel
65 42P Comparative real-world analysis of pembrolizumab plus chemo vs platinum-doublet alone in metastatic non-squamous NSCLC with PD-L1 low Attili, I.
33 S2 p. S51
 artikel
66 102P Comparison of clinical characteristics and prognosis of incidentally detected and screening detected lung cancers Zo, S.
33 S2 p. S79
 artikel
67 124P Comparison of survival among multimodality treatment regimens in malignant pleural mesothelioma patients in an integrated health system Banks, K.
33 S2 p. S89
 artikel
68 115P Concurrent versus sequential immune checkpoint inhibition in stage III NSCLC patients treated with chemoradiation Käsmann, L.
33 S2 p. S86
 artikel
69 190P COVID-19 pandemic impact on lung cancer patient’s performance status and access to treatment: A comparative study pre and during COVID-19 era Fernandes, R.
33 S2 p. S117
 artikel
70 171P Detection of NTRK1/2/3 rearrangements by PCR test for 5’/3’-end unbalanced expression Imyanitov, E.
33 S2 p. S110
 artikel
71 39P Determination of essential biomarkers in lung cancer: A real-world data study in Spain Calvo de Juan, V.
33 S2 p. S50
 artikel
72 140P Development and validation of nomograms based on clinical characteristics and CT reports for preoperative prediction of precision lymph node dissection in lung cancer Tang, H.
33 S2 p. S96
 artikel
73 187P Development of a magnetic nanostructure for co-delivery of metformin and silibinin on growth of lung cancer cells: Possible action through leptin gene and its receptor regulation Jafari-Gharabaghlou, D.
33 S2 p. S116
 artikel
74 90P Disease-free survival (DFS) as a predictor of overall survival (OS) in completely resected early stage non-small cell lung cancer (NSCLC) West, H.
33 S2 p. S74-S75
 artikel
75 67P Distinct concomitant genetic alterations in EGFR-mutant non-small cell lung cancer patients with brain metastases Fan, Y.
33 S2 p. S62
 artikel
76 127P Does radiomics have added value in predicting the development of brain metastases in patients with radically treated stage III non-small cell lung cancer (NSCLC)? Hendriks, L.
33 S2 p. S91
 artikel
77 28P Dose determination and pharmacokinetics (PK) of pralsetinib: Results from the phase I ARROW study Gainor, J.F.
33 S2 p. S44
 artikel
78 27P Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC) Drilon, A.
33 S2 p. S43
 artikel
79 13P Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis Cho, B.C.
33 S2 p. S34-S35
 artikel
80 165P Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens Mazzaschi, G.
33 S2 p. S108
 artikel
81 184P Early-stage diagnosis of lung cancer with liquid biopsy test based on peripheral blood cells Thomsen, A.R.
33 S2 p. S115
 artikel
82 103P Effectiveness of artificial intelligence in retrospective COVID-19 lung CT analysis for lung cancer detection Pirgulov, S.
33 S2 p. S79
 artikel
83 134P Effectiveness of non-pharmacologic strategies for parental smoking cessation to protect children: A systematic review and meta-analysis Caduhada, J.H.
33 S2 p. S94
 artikel
84 143P Efficacy and safety of the anti-PD-L1 monoclonal antibody Socazolimab in combination with carboplatin and etoposide for extensive-stage small cell lung cancer: Results from the phase Ib clinical trial Lu, S.
33 S2 p. S99
 artikel
85 31P Efficacy and safety of utidelone in treatment-refractory advanced non-small cell lung cancer Shi, Y.
33 S2 p. S45-S46
 artikel
86 48P Efficacy of osimertinib (osi) on (prevention of) bone metastases (mets) and skeletal related events (SREs) in patients (pts) with epidermal growth factor receptor mutated (EGFRm+) non-small cell lung cancer (NSCLC) Brouns, A.
33 S2 p. S54
 artikel
87 120P Efficacy of postoperative radiotherapy (PORT) in stage IIIA-N2 non-small cell lung cancer: Meta-analysis of randomized controlled studies Ergün, Y.
33 S2 p. S88
 artikel
88 188P Efficacy of SARS-CoV-2 based mRNA vaccines for patients with thoracic malignancies with 6 months follow up: A prospective observational study Janzic, U.
33 S2 p. S117
 artikel
89 49P EGFR exon 20 insertion mutations in patients with locally advanced or metastatic NSCLC in the German prospective, CRISP Registry real-world cohort (AIO-TRK-0315) Griesinger, F.
33 S2 p. S54-S55
 artikel
90 22P EMB-01: An EGFR-cMET bispecific antibody, in advanced/metastatic solid tumors phase I results Qing, Z.
33 S2 p. S39-S40
 artikel
91 111P Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours Lu, S.
33 S2 p. S83-S84
 artikel
92 137P Epidemiology and histological classification of lung cancer patients in Zimbabwe: A five-year retrospective study at Parirenyatwa Radiotherapy Centre, Harare Mazhindu, T.A.
33 S2 p. S94-S95
 artikel
93 119P Evolution of the management of stage III non-small cell lung cancer (NSCLC): A single-center real-world scenario over 10 years Ferro, A.
33 S2 p. S87
 artikel
94 92P Exploring immune dysfunction in surgically treated early stage NSCLC Sellmer, L.
33 S2 p. S75
 artikel
95 177P Feasibility and usefulness of evaluation of immune status of lung cancer patients by EBUS/TBNA cells analysis Domagala-Kulawik, J.
33 S2 p. S112-S113
 artikel
96 9P Final results from TAIL: Updated long-term safety and efficacy of atezolizumab (atezo) in a diverse population of patients (pts) with previously treated advanced NSCLC Ardizzoni, A.
33 S2 p. S32
 artikel
97 14P Flat-dose nivolumab (NIVO) as second-line (2L) treatment (tx) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC): CheckMate 870 long-term results Lu, S.
33 S2 p. S35-S36
 artikel
98 106P Generation of synthetic ground glass opacities (GGOs) using generative adversarial networks (GANs) Wang, Z.
33 S2 p. S80
 artikel
99 173P Genomic characteristics and its correlations with tumor mutational burden and PD-L1 expression in Chinese lung squamous cell carcinoma Chen, Y.
33 S2 p. S111
 artikel
100 178P Germline genetic variants associated with different premalignant lesions in the bronchial epithelium Gerashchenko, T.S.
33 S2 p. S113
 artikel
101 164P Immune modulatory functions of lurbinectedin in small cell lung cancer and malignant pleural mesothelioma patients Cantini, L.
33 S2 p. S108
 artikel
102 40P Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) patients (pts): A real-world analysis Pretelli, G.
33 S2 p. S51
 artikel
103 63P Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) patients (pts): Neutrophil to lymphocyte ratio (NLR) and the risk for toxicity recurrence Pretelli, G.
33 S2 p. S61
 artikel
104 152P Immunotherapy for extensive-stage SCLC: Uncovering clinical gaps in physician knowledge and practice Harvey-Jones, V.H.J.
33 S2 p. S102
 artikel
105 118P Impact of grade ≥2 pneumonitis (G2+ PNS) on patient reported outcomes (PROs) with durvalumab (D) after chemoradiotherapy (CRT) in unresectable stage III NSCLC Hui, R.
33 S2 p. S87
 artikel
106 146P Impact of heart, lung and oesophageal doses on overall survival (OS) of small cell lung cancer (SCLC) patients following radical chemo-radiotherapy (RT) Tahir, B.A.
33 S2 p. S100
 artikel
107 32P Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis Dafni, U.
33 S2 p. S46-S47
 artikel
108 62P Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small cell lung cancer patients Takamori, S.
33 S2 p. S60
 artikel
109 66P Incidence and impact on survival of venous thromboembolic events in patients with advanced non-small cell lung cancer receiving pembrolizumab as first-line of treatment Hulo, P.
33 S2 p. S62
 artikel
110 36P Indirect comparison of mobocertinib trial data vs real-world data in patients with EGFR exon 20 insertion (ex20ins)+ non-small cell lung cancer (NSCLC) Christopoulos, P.
33 S2 p. S49
 artikel
111 166P Integrated analysis reveals TP53 mutation as a biomarker of anti-PD-1/PD-L1 treatment for epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients Wang, S.
33 S2 p. S108
 artikel
112 167P KRAS G12C lung adenocarcinoma represents a distinct group of patients with different response to immunotherapy Masfarré, L.
33 S2 p. S109
 artikel
113 139P KRAS-G12C NSCLC linked to female sex and high risk of CNS metastasis: Real-world data from the National Swedish Lung Cancer Registry 2016-2019 Isaksson, J.
33 S2 p. S95-S96
 artikel
114 191P Lung cancer care in Europe during COVID-19: Findings from a global survey of patient experience Fenemore, J.
33 S2 p. S117-S118
 artikel
115 136P Lung cancer epidemiology and survival outcomes in Vojvodina, Serbia Bokan, D.
33 S2 p. S94
 artikel
116 197P Lung cancer in lung transplant recipients Svorcova, M.
33 S2 p. S120
 artikel
117 160P LungMetrics India: Molecular epidemiology and testing patterns in 4,773 non squamous NSCLC patients Batra, U.
33 S2 p. S106-S107
 artikel
118 60P Machine learning based on blood biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy Zhou, J-G.
33 S2 p. S59
 artikel
119 130P Metastasis-on-chip: 3D human microvasculature network to study extravasation dynamics of lung cancer in vitro Zeinali, S.
33 S2 p. S92
 artikel
120 194P Modelling strategies to combine multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer van Delft, F.
33 S2 p. S119
 artikel
121 150P Monitoring of PD-L1 expression on circulating immune cells of patients with small cell lung cancer (SCLC) receiving first-line treatment: Prognostic implications Papadaki, M.A.
33 S2 p. S101
 artikel
122 175P Mutations and clinical significance of calcium voltage-gated channel subunit alpha 1E (CACNA1E) in non-small cell lung cancer Wang, G.
33 S2 p. S112
 artikel
123 93P Noncancer-specific mortality in patients with stage IA1 NSCLC after surgical resection: The role of comorbidities in prognosis Huang, W.
33 S2 p. S75-S76
 artikel
124 54P Overall survival in patients with metastatic lung cancer from 2000 to 2020: Implementation of innovative strategies in a real-world setting Basse, C.
33 S2 p. S57
 artikel
125 148P Pathological stage N1 limited-stage small-cell lung cancer patients can benefit from surgical resection Yu, L.
33 S2 p. S101
 artikel
126 83P Pathologic complete response (pCR) after neoadjuvant (neoadj) chemoimmunotherapy (chemo+IO) in resectable non-small cell lung cancer (NSCLC): A systematic review and pooled analysis Rosner, S.
33 S2 p. S72
 artikel
127 112P Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation Bondarenko, I.
33 S2 p. S84-S85
 artikel
128 87P Patient reported physical function (PF) predicts long-term survival in early-stage NSCLC surgical patients Pompili, C.
33 S2 p. S73-S74
 artikel
129 135P Patterns of care and outcomes in immigrants with non-small cell lung cancer Willen, L.
33 S2 p. S94
 artikel
130 45P Pembrolizumab versus best supportive care survival outcomes in ECOG performance status 2 NSCLC patients Elegbede, A.
33 S2 p. S53
 artikel
131 23P Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial Veelen, A.V.
33 S2 p. S40
 artikel
132 142P Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Treatment patterns of chemotherapy combination phase with durvalumab Isla, D.
33 S2 p. S98-S99
 artikel
133 176P Phase transition early-invasive lung cancer and blood cell circuit Kshivets, O.
33 S2 p. S112
 artikel
134 100P Physician perceptions of testing practices in patients with early and advanced stage EGFR mutation-positive (EGFRm) NSCLC: A global survey Bailey, T.
33 S2 p. S77-S78
 artikel
135 71P Predictors of anxiety and depression among advanced lung cancer patients attending palliative care department: An experience from the rural cancer centre Patil, C.R.
33 S2 p. S64
 artikel
136 183P Predictor value of PD-L1 for radiotherapy response in locally advanced non-small cell lung cancer Demircan, V.N.
33 S2 p. S114-S115
 artikel
137 91P Preexisting tumor host immunity delineates clinical outcomes in resectable non-small cell lung cancer Rocha, P.
33 S2 p. S75
 artikel
138 94P Preliminary outcome data for deep inspiratory breath hold guided stereotactic radiotherapy (SBRT) with robotic couch correction for early stage non-small cell lung cancers (NSCLC) Basu, T.
33 S2 p. S76
 artikel
139 15P Preliminary results of histone deacetylase inhibitor tucidinostat combined with PD-1 inhibitor sintilimab in non-small cell lung cancer failed to standard therapies Wang, Y.
33 S2 p. S36
 artikel
140 114P Preliminary results of the “Blue Sky Radiomics” study on stage III NSCLC patients treated with chemo-radiation and consolidation immunotherapy Filippi, A.R.
33 S2 p. S85
 artikel
141 138P Prevalence and characteristics of lung cancer in families harboring pathogenic germline variants in cancer predisposing genes Laguna Montes, J.C.
33 S2 p. S95
 artikel
142 46P Prognostic impact of immune checkpoint inhibition in patients with metastatic non-small cell lung cancer (NSCLC): Real-world study in central Switzerland Allmann, V.
33 S2 p. S53
 artikel
143 117P Prognostic value of new grading system in resected lung adenocarcinoma after neoadjuvant therapy E, H.
33 S2 p. S86
 artikel
144 41P Progression after chemo-IO and durvalumab in stage III non-small cell lung cancer (NSCLC): What should be the next line? Real-world study Shentzer Kutiel, T.
33 S2 p. S51
 artikel
145 113P Proton-therapy and concurrent chemotherapy in stage III NSCLC: Effects on durvalumab eligibility and safety profile Cortiula, F.
33 S2 p. S85
 artikel
146 174P Pulmonary tuft cell-like cancers across different histotypes share molecular features with potentially druggable vulnerabilities Yamada, Y.
33 S2 p. S111-S112
 artikel
147 195P Radiomics and dosiomics signature from whole lung predicts radiation pneumonitis: A model development study with prospective external validation and decision-curve analysis Zhang, Z.
33 S2 p. S119
 artikel
148 125P Radiomic signature from baseline CT Scan to predict initial response to treatment in advanced/unresectable pleural mesothelioma: Preliminary data Catino, A.
33 S2 p. S89-S90
 artikel
149 192P Randomized, phase II, placebo-controlled trial of nintedanib for the treatment of radiation pneumonitis Moore, Z.R.
33 S2 p. S118
 artikel
150 18P RATIONALE-307: Safety analysis of patients (pts) receiving tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone in advanced squamous (sq) NSCLC Yu, X.
33 S2 p. S37-S38
 artikel
151 201P Readability of thoracic surgery consent forms in Queensland, Australia Dutta, S.
33 S2 p. S121
 artikel
152 144P Real-world data of consolidative radiotherapy for extensive stage (ES)-SCLC treated by chemo-immunotherapy (chemo-IO) Daher, S.N.
33 S2 p. S99-S100
 artikel
153 158P Real-world management of patients with EGFR exon 20-mutant NSCLC in the precision oncology era: First report from the European EXOTIC registry Mountzios, G.
33 S2 p. S105-S106
 artikel
154 47P Real-world outcomes of immune checkpoint inhibitors and selective RET inhibitors for RET fusion non-small cell lung cancer Wan, R.
33 S2 p. S54
 artikel
155 116P Real-world outcomes with durvalumab (durva) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC (SPOTLIGHT) Mooradian, M.
33 S2 p. S86
 artikel
156 151P Real-world patient eligibility for lurbinectedin/doxorubicin in small cell lung cancer Rittberg, R.
33 S2 p. S101-S102
 artikel
157 44P Real-world (RW) treatment patterns, patient characteristics and outcomes in advanced non-small cell lung cancer (aNSCLC) with PD1/L1 as first-line (1L) therapy in the UK and Germany Snee, M.
33 S2 p. S52-S53
 artikel
158 35P Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins) Kim, T.M.
33 S2 p. S48
 artikel
159 129P Regulatory dendritic cells correlate with an altered T cell distribution and regulatory T cell phenotype in metastatic lymph nodes of NSCLC patients Raniszewska, A.
33 S2 p. S92
 artikel
160 11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts Krebs, M.G.
33 S2 p. S33
 artikel
161 34P RET-MAP: An international multi-center study on clinicopathologic features and treatment response in patients with NSCLC and RET fusions Marinello, A.
33 S2 p. S47-S48
 artikel
162 159P ReWARD study - Real-world ALK-resistance data: A single center experience Batra, U.
33 S2 p. S106
 artikel
163 20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC) Trigo, J.
33 S2 p. S38-S39
 artikel
164 95P Role of postoperative follow-up with 18F-FDG PET/CT in asymptomatic NSCLC patients: A retrospective single institution study Kaumanns, A.
33 S2 p. S76
 artikel
165 52P ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics Glaser, M.
33 S2 p. S56-S57
 artikel
166 193P Safety and efficacy of immmunotherapy rechallenge following a previous immune-induced interstitial lung disease Joseph, C.
33 S2 p. S118-S119
 artikel
167 17P Safety and tolerability of sintilimab (sint) combination therapy in patients with advanced or recurrent non-small cell lung cancer (NSCLC): Pooled safety analysis of ORIENT 11 and ORIENT 12 studies Gao, G.
33 S2 p. S37
 artikel
168 153P Safety profile and associated costs of therapies for relapsed small cell lung cancer in Switzerland Jörger, M.
33 S2 p. S102
 artikel
169 180P Schwann cells promotes tumour progression in small cell lung cancer Cao, S.
33 S2 p. S113-S114
 artikel
170 53P Second-line treatment in advanced non-squamous (NS) non-small cell lung cancer (NSCLC) patients in Spain, analyzed in the Thoracic Tumor Registry (RTT) Carcereny Costa, E.
33 S2 p. S57
 artikel
171 84P SHR-1316 vs placebo in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: A randomized, double-blind, multicenter, phase Ib/III trial Wu, Y-L.
33 S2 p. S72
 artikel
172 56P Simultaneous tissue and liquid next-generation sequencing after first-line EGFR tyrosine kinase inhibitors resistance in advanced non-small cell lung cancer Lin, Y-T.
33 S2 p. S58
 artikel
173 21P Sintilimab in combination with anlotinib in non-small cell lung cancer patients with uncommon EGFR mutations: A phase II, single-arm, prospective study Chen, K.
33 S2 p. S39
 artikel
174 37P Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer Chour, A.
33 S2 p. S49-S50
 artikel
175 19P Stable disease (SD) on amivantamab in post-platinum epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutated non-small cell lung cancer (NSCLC): A response-based analysis Girard, N.
33 S2 p. S38
 artikel
176 128P Surgical management of lung metastases: A work-in-progress report from an international ESTS research group Prisciandaro, E.
33 S2 p. S91-S92
 artikel
177 25P Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping Yang, J.C-H.
33 S2 p. S41-S42
 artikel
178 24P Tepotinib in patients with MET exon 14 skipping NSCLC: Efficacy and safety by line of therapy Griesinger, F.
33 S2 p. S40-S41
 artikel
179 51P Testing patterns and outcomes of different EGFR-positive metastatic non-small cell lung cancer (NSCLC) patients in a Canadian real-world setting Boyne, D.J.
33 S2 p. S56
 artikel
180 38P The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): Differences between KRAS G12C and non-G12C Notario Rincon, L.
33 S2 p. S50
 artikel
181 55P The impact of liquid next-generation testing timing on treatment-naïve advanced non-small cell lung cancer: A prospective observational study Yang, C.
33 S2 p. S58
 artikel
182 104P The potential for lung cancer detection in COVID-19 CT scans with AI technologies usage Zinovev, S.V.
33 S2 p. S79
 artikel
183 182P Therapeutic activity of thiostrepton in patient-derived malignant pleural effusions Cunniff, B.
33 S2 p. S114
 artikel
184 199P The relative impact of surgery history on cancer risk in patients less than 60 years old Wang, H.
33 S2 p. S120-S121
 artikel
185 72P The risk factors of developing severity in immune checkpoint inhibitors-related pneumonitis in advanced lung cancer patients Zhang, Y.
33 S2 p. S64
 artikel
186 99P The value of disease free survival (DFS) and osimertinib in adjuvant non-small cell lung cancer (NSCLC): An international Delphi consensus report Hardenberg, M.
33 S2 p. S77
 artikel
187 200P The value of holistic assessment and rapid intervention: The lung cancer outpatient occupational therapy service (LCOOTS) Welford, J.
33 S2 p. S121
 artikel
188 97P TNFSF14 overexpression and poor prognosis in early stages of non-small cell lung cancer prognosis: Immune-checkpoint inhibitor databases-based study Safi, M.
33 S2 p. S77
 artikel
189 149P Total metabolic tumor volume: A new potential prognostic factor in SCLC Andrini, E.
33 S2 p. S101
 artikel
190 96P Transbronchial microwave ablation: Important role in the battle of lung preservation for multifocal lung primaries or metastases Chan, J.W.Y.
33 S2 p. S76-S77
 artikel
191 10P Treatment-free survival (TFS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with 1L nivolumab plus ipilimumab (NIVO+IPI) or platinum doublet chemotherapy (PDC) in CheckMate (CM) 227 Peters, S.
33 S2 p. S32-S33
 artikel
192 121P Treatment of unresectable stage III NSCLC: Real-world study and literature review Verfaillie, S.
33 S2 p. S88
 artikel
193 89P Treatment patterns, overall survival (OS), and disease-free survival (DFS) in early stage non-small cell lung cancer (NSCLC) following complete resection West, H.
33 S2 p. S74
 artikel
194 133P Trends in incidence and mortality of lung cancer in Switzerland: Possible explanations and open questions Frisone, D.
33 S2 p. S93-S94
 artikel
195 69P Tumor invasiveness, response to ALK inhibitors and resistance mechanism in NSCLC with different ALK variants Zou, Z.
33 S2 p. S63
 artikel
196 88P Uncertain resection for localized cN0M0 non-small cell lung cancer: The crucial prognosis of suboptimal lymph node assessment Vergé, R.
33 S2 p. S74
 artikel
197 61P Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib Moreno, V.
33 S2 p. S60
 artikel
198 110P Updated efficacy and safety of entrectinib in patients (pts) with NTRK fusion-positive (NTRK-fp) NSCLC Cho, B.C.
33 S2 p. S82-S83
 artikel
199 43P Update on long term outcome of a multicentre, prospective, real-world study of camrelizumab in the treatment of patients with advanced lung cancer Shu, Y.
33 S2 p. S51-S52
 artikel
200 132P 20 years of real life nationwide epidemiological data on lung cancer in non-academic French public hospitals: KBP-2020-CPHG compared to 2000 and 2010 studies Debieuvre, D.
33 S2 p. S93
 artikel
201 Table of Contents
33 S2 p. vi
 artikel
202 154TiP AdvanTIG-204: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus anti-PD-1 mAb tislelizumab (TIS) plus concurrent chemoradiotherapy (cCRT) in patients (pts) with untreated limited-stage small cell lung cancer (LS-SCLC) Lu, Y.
33 S2 p. S103
 artikel
203 156TiP An open-label, single-arm, phase II study evaluating the efficacy and safety of niraparib combined with radiotherapy and teriprizumab in patients with recurrent small cell lung cancer Zeng, W.
33 S2 p. S104
 artikel
204 79TiP A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations Opdam, F.
33 S2 p. S69-S70
 artikel
205 74TiP Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC/IV EGFR-mutant, T790M-negative, MET-amplified NSCLC Wu, Y-L.
33 S2 p. S64-S65
 artikel
206 78TiP Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study Besse, B.
33 S2 p. S68-S69
 artikel
207 75TiP Open-label, phase II study of tusamitamab ravtansine (SAR408701) in combination with pembrolizumab and with pembrolizumab + platinum-based chemotherapy +/− pemetrexed in patients with CEACAM5-positive nonsquamous NSCLC (CARMEN-LC05) Paz-Ares, L.
33 S2 p. S65-S66
 artikel
208 122TiP Phase III study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG 3515) Robinson, C.
33 S2 p. S88
 artikel
209 155TiP Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE®) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC) Ramalingam, S.S.
33 S2 p. S103-S104
 artikel
210 76TiP RMC-4630 and sotorasib for advanced KRASG12C NSCLC after failure of prior standard therapies: A phase II trial Johnson, M.L.
33 S2 p. S66-S67
 artikel
211 77TiP TRUST-II: A global phase II study for taletrectinib in ROS1 fusion-positive lung cancer and other solid tumors Nagasaka, M.
33 S2 p. S67-S68
 artikel
212 Title Page
33 S2 p. iv
 artikel
                             212 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland